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The family of tissue inhibitors of metalloproteinases
(TIMPs) exhibits diverse physiological/biological func-
tions including the inhibition of active matrix metallopro-
teinases, regulation of proMMP activation, cell growth,
and the modulation of angiogenesis. TIMP-1 is a secret-
ed protein that can be detected on the cell surface
through its interaction with surface proteins. The diverse
biological functions of TIMP-1 are thought to lie, in part,
in the kinetics of TIMP-1/MMP/surface protein interac-
tions. Proteins anchored by glycoinositol phospholipids
(GPIs), when purified and added to cells in vitro, are
incorporated into their surface membranes. A GPI anchor
was fused to TIMP-1 to generate a reagent that could be
added directly to cell membranes and thus focus defined
concentrations of TIMP-1 protein on any cell surface
independent of protein-protein interaction. Unlike native
TIMP-1, exogenously added GPI-anchored TIMP-1 pro-
tein effectively blocked release of MMP-2 and MMP-9
from osteosarcoma cells. TIMP-1-GPI was a more effec-
tive modulator of migration and proliferation than TIMP-
1. While control hTIMP-1 protein did not significantly
affect migration of primary microvascular endothelial
cells at the concentrations tested, the GPI-anchored
TIMP-1 protein showed a pronounced suppression of
endothelial cell migration in response to bFGF. In addi-
tion, TIMP-1-GPI was more effective at inducing micro-
vascular endothelial proliferation. In contrast, fibroblast
proliferation was suppressed by the agent. Reagents
based on this method should assist in the dissection of
the protease cascades and activities involved in TIMP
biology. Membrane-fixed TIMP-1 may represent a more
effective version of the protein for use in therapeutic
expression.
Keywords: cell painting; GPI anchor; MMP;
proliferation; TIMP-1.
Introduction
The matrix metalloproteinase (MMP) superfamily is rep-
resented by at least 26 extracellular matrix-degrading
metalloendopetidases (Visse and Nagase, 2003). Collec-
tively these enzymes are responsible for the metabolism
of extracellular matrix proteins (Visse and Nagase, 2003).
MMPs are active during tissue development and differ-
entiation, cellular infiltration, wound healing, and act as
moderators of the immune response (Opdenakker et al.,
2001; Visse and Nagase, 2003). These enzymes have
also been implicated in chronic disease processes such
as multiple sclerosis and rheumatoid arthritis as well as
in tumor progression and metastasis (Curran and Murray,
2000; Galis and Khatri, 2002; Itoh and Nagase, 2002;
Ikeda and Shimada, 2003).
The activity of MMPs is kept under tight biological con-
trol (Nagase and Woessner, 1999). MMPs are regulated
at the level of gene expression, protein synthesis, com-
partmentalization of enzyme activity and the processing
of MMP pro-enzymes (Nagase and Woessner, 1999; Vis-
se and Nagase, 2003). In addition, in cell membranes and
within extracellular spaces MMPs are regulated by the
expression/presence of natural MMP inhibitors, the tis-
sue inhibitors of matrix metalloproteinases (TIMPs)
(Gomez et al., 1997; Visse and Nagase, 2003). Four TIMP
family members have been identified: TIMP-1, TIMP-2,
TIMP-3 and TIMP-4 (Brew et al., 2000; Bode and Mas-
kos, 2003). These inhibitors share structural similarities
but show different specificity and tissue expression (Brew
et al., 2000; Bode and Maskos, 2003). TIMP-1 is the
most widely distributed TIMP and, with the exception of
MT1-MMP, inhibits the activity of all other MMPs (Brew
et al., 2000; Visse and Nagase, 2003). TIMP-1 is a soluble
protein, but it can be detected on the cell surface through
its interaction with surface-bound structures (Brew et al.,
2000; Klier et al., 2001). TIMP-1 has been shown to
exhibit growth factor-like activity and has been linked to
angiogenesis, cell migration, proliferation, tumor growth
and metastasis (Forough et al., 1996; Gomez et al., 1997;
Fernandez et al., 1999; Lijnen et al., 1999; Guedez et al.,
2001; Bloomston et al., 2002; Lambert et al., 2003).
Protein engineering of cell surfaces is a powerful tool
for the study of protein function (Medof et al., 1996). Pro-
teins anchored by glycosylphosphatidylinositol (GPI),
when purified and added to cells in vitro, are incorporat-
ed into their surface membranes (Medof et al., 1996; Pre-
mkumar et al., 2001). The incorporability of these
molecules into cell surfaces provides a general means for
modifying cell surfaces with exogenously added func-
tional determinants. We combined TIMP-1 with a GPI
anchor to generate a flexible inhibitory reagent that could
be used to selectively moderate cell surface proteolytic
environments. This approach provides the basis for the
generation of a set of novel reagents to assess TIMP and
MMP biology.
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Figure 1 Generation and purification of GPI-anchored TIMP-1.
(A) The GPI-anchored TIMP-1 was overexpressed in CHO cells. The FACS plot of stably transfected CHO cells using an anti-human
TIMP-1 monoclonal antibody is shown. (B) In parallel to the experiment shown in (A), TIMP-1-GPI expressing CHO cells were treated
with 60 ng/ml phosphatidylinositol-specific phospholipase C for 30 min before FACS analysis using the anti-human TIMP-1 antibody.
(C) The GPI-anchored TIMP-1 CHO cells were treated with 0, 30, 60, 120 ng/ml phosphatidylinositol-specific phospholipase C in
serum-free media for 30 min at 378C. TIMP-1 was measured in the supernatant using a human TIMP-1-specific ELISA kit. Data
represent the mean of ns3 experiments. (D) Outline of the procedure used to purify the TIMP-1-GPI protein from the CHO overex-
pressing cells using fast protein liquid chromatography (FPLC). Protein was detected by silver stain and human TIMP-1 protein by
Western blotting using an anti-human TIMP-1 monoclonal antibody. The fraction numbers listed for the silver stain and Western blot
each represent 0.25 ml of the size exclusion column from 5.25 to 7.5 ml.
Results
Construction and purification of the TIMP-1-GPI
fusion protein
The human TIMP-1 gene was cloned from cDNA using
hTIMP-1-specific primers (see materials and methods
section). The TIMP-1 cDNA sequence (without a trans-
lation stop codon) was fused to a GPI signal sequence
cloned from LFA-3 cDNA (Kirby et al., 1995; Medof et al.,
1996). The resulting fusion construct was then cloned
into pEF-DHFR (Mack et al., 1995), and stably introduced
into DHFR-deficient Chinese hamster ovary (CHO) cells.
Stable transfectants were selected as described (Mack
et al., 1995). Surface TIMP-1 expression was determined
by fluorescence-activated cell sorting (FACS) analysis
using a hTIMP-1-specific antibody (Klier et al., 2001) (Fig-
ure 1A). GPI anchorage was confirmed using TIMP-1
FACS analysis (Figure 1B) and a TIMP-1-specific ELISA
of the growth media (Figure 1C) following 30 min PI-PCL
(phosphatidylinositol-specific phospholipase) digestion.
TIMP-1-GPI-fusion protein was purified from the trans-
fected cells by Triton X-100 (hydrogenated) detergent
extraction followed by column purification using DEAE,
heparin Sepharose and size exclusion chromatography
(Medof et al., 1996). The general purification scheme is
outlined in Figure 1D (and the materials and methods
section). The resultant protein was identified by Western
blot analysis and silver staining (Figure 1D). Quantifica-
tion of the protein concentration using Bradford protein
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 11:56
Biological activity of GPI-anchored TIMP-1 protein 657
Figure 2 TIMP-1-GPI incorporation.
To demonstrate reincorporation of the GPI-TIMP-1 protein into
cell membranes, the purified TIMP-1-GPI protein or recombinant
human TIMP-1 was added to native CHO cells and human
TIMP-1 detected on the cell surface by FACS analysis. (A) Exam-
ple FACS after addition of 200 ng/ml TIMP-GPI or (B) 200
ng/ml rhTIMP-1 protein. (C) The plot of mean channel fluores-
cence vs. concentration of TIMP-1-GPI used demonstrates a
dose-dependent localization of the GPI-anchored protein on the
cell surface.
assay as compared to the level of TIMP-1 protein deter-
mined using TIMP-1 ELISA showed the protein to be over
90% pure (data not shown).
Exogenously added TIMP-1-GPI-anchored protein is
incorporated into cell membranes in a dose-
dependent manner
To demonstrate reincorporation of the GPI-TIMP-1 pro-
tein into cell membranes, 200 ng/ml of purified TIMP-1-
GPI or rhTIMP-1 protein was added to CHO cells and
TIMP-1 protein was detected on the cell surface using
FACS (Figure 2A and B). Addition of increasing concen-
trations of TIMP-1-GPI shows a dose dependent incor-
poration of the GPI-anchored protein into the cell surface
(Figure 2C).
Human TIMP-1 ELISA was used to determine the
amount of protein associated with the CHO cells follow-
ing incubation with 200 ng/ml or 700 ng/ml of either
TIMP-1-GPI or rTIMP-1 protein. Cell supernatant was
harvested and subjected to analysis. The TIMP-1-GPI
protein efficiently bound to the CHO cells (approximately
90% of starting material associated with the CHO cells)
while control rTIMP-1 protein showed no binding to the
CHO cells (Table 1).
The TIMP-1-GPI protein blocks release of MMP-2
and MMP-9 in the U-2 OS osteosarcoma cell line
following incorporation into the cell membrane
Native TIMP-1 is a soluble protein but it can be detected
on the surface of cells through its association with other
proteins, such as proteases, that are cell surface asso-
ciated. The osteosarcoma cell line U-2 OS secretes both
MMP-2 and MMP-9 constitutively (Figure 3B). We tested
the effect of surface incorporated TIMP-1 on the consti-
tutive secretion of these proteins using gelatinase zym-
ography. The osteosarcoma cell line was treated with
increasing concentrations of TIMP-1-GPI. FACS analysis
showed a shift corresponding to an increasing incorpo-
ration of the GPI-anchored protein (Figure 3A). Subse-
quently the secretion of MMP-2 and MMP-9 into the
culture supernatant was assessed. The results show that
recombinant hTIMP-1 protein at 600 or 1200 ng/ml had
no effect on the secretion of MMP-2 or MMP-9. In con-
trast, at 10 ng/ml TIMP-1-GPI demonstrates a significant
reduction in the release of both MMP-2 and MMP-9 into
the growth media. Increasing TIMP-1-GPI resulted in a
dose-dependent reduction in MMP-2 and MMP-9 secre-
tion. At TIMP-1-GPI levels above 240 ng/ml no MMP-2
or MMP-9 could be detected in the growth media (Figure
3B).
This effect appears to be due at least in part to seques-
tration of the proteases on the cell surface by membrane-
bound TIMP-1. Following incubation of U-2 OS cells with
700 ng/ml of purified hTIMP-1-GPI protein for 24 h, FACS
analyses using MMP-2- and MMP-9-specific antibodies
showed an increase in mean channel fluorescence signal
for TIMP-1, MMP-2 and MMP-9 from (Figure 3C). While
these results show an increase of MMP-2 and MMP-9
protein on the cell surface, they do not rule out additional
effects on signal transduction, mRNA transcription or
protein expression.
Substrate assays for MMP-2 and MMP-9 enzymatic
activity demonstrate that GPI-anchored TIMP-1 is
functionally equivalent to recombinant TIMP-1
Fusion of a GPI anchor to the carboxy-terminus of TIMP-
1 could influence the ability of the resultant fusion protein
to inhibit protease activity. To address this, a commercial
gelatinase substrate assay system (Molecular Probes E-
12055) was used to compare and contrast the inhibitory
properties of hTIMP-1-GPI to rhTIMP-1 to the suppres-
sion of recombinant MMP-2 and MMP-9 enzymatic
activity.
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Table 1 Determination of TIMP-1 incorporation by ELISA.
Protein added to Total TIMP-1 Total TIMP-1 Calculated TIMP-1
2.25=106 CHO protein protein/105 protein in TIMP-1 protein incorporated
cells (ng/ml) (ng) cells (ng) supernatant bound per 105 into cells (%)
(ng) cells (ng)
1 Control 0 0 0 0 0
2 200 TIMP-1-GPI 60 2.66 3"0.3 2.53"0.87 95
3 700 TIMP-1-GPI 210 9.33 22.5"0.01 7.35"0.01 89
4 200 rhTIMP-1 60 2.66 60"1.3 0 0
5 700 rhTIMP-1 210 9.33 210"3.8 0 0
Following a 2 h incubation the efficiency of incorporation TIMP-1-GPI as compared to rTIMP-1 into CHO
cells was determined using human TIMP-1-specific ELISA. The protein bound to CHO was calculated by
subtracting protein detected in the cell supernatant and wash supernatant from the starting concentration.
The assay uses a quenched, fluorescently labeled gel-
atin (see materials and methods). Two mmol of recom-
binant MMP-2 or MMP-9 in 100 ml were used to
establish an arbitrary 100% fluorescence signal linked to
digestion of the substrate for each enzyme. Increasing
levels of TIMP-1-GPI or rTIMP-1 inhibitors (0.5–30 mmol)
were added to parallel wells at time zero and fluores-
cence measured every 30 min over 120 min. The result-
ing data showed similar results for the rhTIMP-1 and
TIMP-1-GPI proteins with respect to their ability to sup-
press MMP-2 and MMP-9 activities (Figure 4A and B).
Addition of the GPI anchor does not appear to signifi-
cantly diminish or enhance the function of TIMP-1 in a
soluble substrate assay.
The GPI-anchored TIMP-1 protein is significantly
more potent at stimulating endothelial cell
proliferation than rhTIMP-1
TIMP-1-GPI can integrate into cell membranes and
appears functionally active and should therefore focus
TIMP-1 activity on the cell surface. This may result in a
more pronounced effect on those biologic parameters
dependent on cell surface protease activity. TIMP-1 has
been shown to mediate angiogenesis (Ikenaka et al.,
2003; Reed et al., 2003; Visse and Nagase, 2003). The
effect of TIMP-1-GPI on the proliferation of primary
human microvascular endothelial cells was compared to
soluble TIMP-1 at 24, 48 and 72 hs using a MTT cell
proliferation assay (Figure 5A).
Exogenously added TIMP-1-GPI protein elicited a
dose-dependent increase in the proliferation of micro-
vascular endothelial cells with a maximal effect seen at
600 ng/ml. At approx. the same concentration, rTIMP-1
showed a substantially lower effect and that treated
TIMP-1-GPI had no effect (Figure 5A). The optimal stim-
ulatory effect was seen at 24 h after addition of the TIMP
proteins. This suggests that by focusing the bioactivity
of TIMP-1 onto the cell surface it is approx. 3- to 4-fold
more effective in increasing the proliferation of microvas-
cular endothelial cells.
The proliferative effects of TIMP-1 have been shown
to be dependent, to some degree, on the cell type used
(Hayakawa et al., 1992). To evaluate the general effect of
TIMP-1-GPI on cellular proliferation, the effect on primary
human dermal fibroblasts was then determined. Here the
results were quite different. Both the GPI anchored and
recombinant TIMP-1 protein showed a slight suppression
of cell proliferation after 24 h at similar protein concen-
trations, but a pronounced suppression of proliferation
was seen with the GPI-anchored protein by the 72 h time
point (Figure 5B).
The TIMP-1-GPI protein is significantly more
effective at inhibiting microvascular endothelial cell
migration than is rhTIMP-1
Proteolysis of vascular basement membranes and the
surrounding extracellular matrix is a critical early step in
neovascularization (Nguyen et al., 2001). It requires alter-
ation in the balance between MMPs and TIMPs (Gomez
et al., 1997; Nguyen et al., 2001). TIMP-1 has been pre-
viously shown to have both positive and negative effects
on neovascularization (Collen et al., 2003; Ikenaka et al.,
2003; Reed et al., 2003). We studied the effect of the
GPI-anchored TIMP-1 protein on the migration of human
microvascular endothelial cells (huMVECs) driven by
bFGF. A potent suppression of migration was seen fol-
lowing treatment with the TIMP-1-GPI agent (Figure 6).
The addition of 540 ng/ml recombinant TIMP-1 resulted
in an approx. 50% decrease in huMVEC migration. By
contrast, the addition of 10 ng/ml of TIMP-1-GPI dra-
matically suppressed huMVEC migration, and at 270 ng/
ml a complete suppression of migration was seen (Figure
6). In additional control experiments, the effect of 600 ng/
ml heat-treated TIMP-1-GPI was compared to the same
concentration of rhTIMP-1, or TIMP-1-GPI, in the sup-
pression of bFGF induced endothelial cell migration at
the four h time point. The heat-treated protein or recom-
binant protein showed no significant reduction in migra-
tion while the TIMP-1-GPI anchored protein resulted in a
90% suppression of migration (data not shown).
Discussion
TIMP-1, a 184-residue protein, was initially identified as
an erythroid potentiating activity that was later shown to
either promote or inhibit cell proliferation and migration
depending upon the biologic settings (Dean and Woes-
sner, 1984; Gasson et al., 1985; Bertaux et al., 1991;
Hayakawa et al., 1992; Yamada et al., 2001). The protein
was subsequently found to moderate MMP activity and
to be a member of the TIMP family of MMP inhibitors
(Dean and Woessner, 1984; Hayakawa et al., 1992; Brew
et al., 2000). TIMP-1 is normally secreted, but it can also
be found on cell surfaces when complexed with surface-
associated proteins. We sought to combine TIMP-1 with
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Figure 3 TIMP-1-GPI modulation of MMP-2 and MMP-9 release from U-2 OS cells.
(A) The purified hTIMP-1-GPI protein is integrated into the membrane of the osteosarcoma cell line U-2 OS and shows an increase
in surface expression by TIMP-1 FACS with increasing concentrations of protein used. (B) TIMP-1-GPI protein incorporated into the
U-2 OS osteosarcoma cell line leads to a reduction in MMP-2 and MMP-9 release into the growth media. Zymography was used to
study the secretion of MMP-2 and MMP-9 from the cell line. 50 000 cells were placed into a 24-well plate and increasing TIMP-GPI
or control rTIMP-1 was added. After 48 h the culture supernatant was removed and analyzed. (C) FACS analysis following incubation
of U-2 OS cells with 700 ng/ml for 24 h showed an increase in surface staining for MMP-2, MMP-9 as well as TIMP-1.
a GPI anchor to generate a flexible and efficient reagent
to characterize the biologic effect of focusing the inhibitor
on the cell surface irrespective of protein-protein
interactions.
Reincorporation of purified GPI-anchored TIMP-1 pro-
tein into cells was efficient (approx. 90% of protein
bound to CHO cells) while exogenously added rTIMP-1
was not detectable on the CHO cells. Incorporation of
purified TIMP-1-GPI into osteosarcoma cells was found
to block, in a dose-dependent manner, the release of
proMMP-2 and proMMP-9 into the growth medium.
Parallel FACS analysis showed an increase in surface
staining for MMP-2 and MMP-9 antigens following incor-
poration of TIMP-1-GPI protein. This suggests that the
reduction in the release of these proteins may be due in
part to a sequestering of the proteases on the cell sur-
face by the membrane bound TIMP-1. Interestingly, while
TIMP-1 can suppress MMP-2 activity, it has not been
shown to bind efficiently to the pro-enzyme form of
MMP-2 (Bode et al., 1999; Nagase and Woessner, 1999).
Modification of TIMP-1 with a GPI anchor appears may
alter or enhance the ability of the TIMP-1 protein to bind
proMMP-2.
Endothelial cell invasion is an essential event during
angiogenesis (formation of new blood vessels) (Brew et
al., 2000; Nguyen et al., 2001; Reed et al., 2003). The
process involves degradation of the basement
membrane and the underlying interstitium. MMP-2 and
MMP-9 have both been shown to play roles in angioge-
nesis (Collen et al., 2003). Latent MMP-9 can be secreted
from endothelial cells and will accumulate in the cytosol
as an active enzyme, free of TIMP-1. Latent MMP-2 is
constitutively secreted from the cells (Collen et al., 2003).
We assessed the effect of exogenously added TIMP-
1-GPI on primary microvascular endothelial cell migration
and proliferation. While control rhTIMP-1 protein did not
significantly effect migration at the concentrations tested,
the GPI-anchored TIMP-1 protein showed a pronounced
suppression of endothelial cell migration in response to
bFGF. GPI-anchored TIMP-1 was found to dramatically
stimulate endothelial cell proliferation, while rhTIMP-1
had little or no effect. TIMP-1 is a stable protein (Dean
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Figure 4 Functional in vitro assay of TIMP-1 activity.
This assay was used to contrast the inhibitory activity of GPI-
anchored TIMP-1 with recombinant TIMP-1. A gelatinase sub-
strate assay system and recombinant MMP-2 (A) and MMP-9
(B) was used to compare the inhibition of gelatinase activity.
Recombinant hTIMP-1 and TIMP-1-GPI show essentially equiv-
alent suppression of gelatinase activity. Data represent the mean
of ns6 experiments.
and Woessner, 1984). In the experiments detailed here,
heating the TIMP-1-GPI fusion protein at 908C for 30 min
was found to be sufficient to disrupt the enhanced activ-
ity associated with addition of the GPI anchor.
TIMP-1 has been shown to have diverse biologic
effects and the effects can differ from cell type to cell
type. This dichotomy of TIMP-1 bioactivity was further
demonstrated when the effect of the GPI-anchored pro-
tein was assessed on fibroblast proliferation. Unlike the
induction of proliferation seen in the primary microvas-
cular endothelial cells, TIMP-1-GPI was found to sup-
press proliferation of primary dermal fibroblasts after
incubation for 72 h.
TIMP-1 is a multifunctional protein (Sobue et al., 2001).
TIMP-1 confers resistance to Fas-ligand-dependent and
-independent apoptosis in Burkitt’s lymphoma (Guedez
et al., 1998). The overall role of TIMP-1 in cancer biology
remains the subject of conflicting reports with both an
anti-tumor activity and a tumor growth-stimulation activ-
ity by several mechanisms (Hayakawa et al., 1992; Gued-
ez et al., 2001; Bloomston et al., 2002; Ikenaka et al.,
2003; Seiki, 2003). TIMPs possess both proteolytic inhib-
itory activities and other functions. Their biology is being
exploited in the search for novel therapeutic strategies
with the hope that, by altering the MMP/TIMP balance,
disease progression can be modulated. To this end an
increase in the local concentration of TIMPs by recom-
binant protein administration or gene transfer is an option
that has shown efficacy in animal models and may have
broad clinical potential.
Studies of the structural basis of the interactions of
TIMPs and MMPs are providing clues for tuning the biol-
ogy of TIMP-1 and other TIMPs for potential therapeutic
use. Combinations of mutations in the major MMP-bind-
ing region that enhance the specificity of TIMP-1 show
improved selectivity or binding affinity to specific MMPs
(Nagase and Brew, 2002; Wei et al., 2003). By exploiting
point mutations it has been possible to uncouple the ery-
throid precursor growth stimulation activity from protease
inhibition (Wei et al., 2003). The addition of a GPI anchor
represents an additional modification of the native TIMP-
1 protein that when combined with site-specific muta-
tions will result in a dramatic biologic effect.
Materials and methods
Cell lines and cell culture
DHFR-deficient Chinese hamster ovary cells (CHO/dhfr-) (ATCC,
Rockville, USA; no. CRL.9096) were cultured in complete
a-medium (GIBCO BRL, Life Technologies GmbH, Eggenstein,
Germany) supplemented with 10% heat-inactivated dialyzed
FCS (GIBCO BRL, Life Technologies GmbH) and HT supplement
(GIBCO BRL, Life Technologies GmbH). U-2 OS cells (ATCC; no.
HTB 96) were cultured in RPMI 1640 medium (GIBCO BRL, Life
Technologies GmbH) supplemented with 10% heat-inactivated
FCS (Biochrom KG, Berlin, Germany). Primary human dermal
fibroblast cells NHDF-c (PromoCell, Heidelberg, Germany) were
cultured in DULBECCO’S MEM with Glutamax-1 (GIBCO BRL,
Life Technologies GmbH) supplemented with 10% heat-inacti-
vated FCS. Human microvascular endothelial cells (PromoCell)
were cultured in Endothelial Cell Growth Medium (PromoCell),
supplemented with 10% heat-inactivated FCS.
Plasmid construction and stable expression in CHO
(dhfr- CRL)
A DNA fragment encoding the signal for GPI-anchor attachment
of LAF3 was amplified by PCR and cloned into the pEF-DHFR
vector (Mack et al., 1995). The sense primer corresponded to
nucleotides 616–633 and contains an XbaI restriction site
(underlined): 59-TCT TTG GAG ARG AGC TCT AGA ACA ACC
TGT ATC CCA AGC AG-39. The antisense primer corresponded
to nucleotides 860–877 and contains a SalI site (underlined): (59-
TCC CGC GGC CGC TAT TGG CCG ACG TCG ACT CAT AAT
ACA TTC ATA TAC AGC ACA ATA CAT GTT G-39. A DNA frag-
ment encoding hTIMP-1 but excluding the stop codon was
amplified by PCR from cDNA. The sense primer corresponded
to nucleotides 36–44, including the initiation codon for human
TIMP-1 with a modification to include an EcoRI restriction site
(underlined): 59-GAA CCC ACC GAA TTC ATG GCC CCC T-39.
The antisense primer corresponded to nucleotides 653–666 of
human TIMP-1 with the introduction of an XbaI site (underlined):
59-GGC GCC TCT AGA GGC TAT CTG GGA CC-39. The GPI
anchor signal sequence and fusion contributed nine additional
amino acids to the carboxyl end of TMP-1 (MSRTTCIPS). The
amplified gene sequences were subcloned sequentially into the
pEF-DHFR vector and introduced into CHO (dhfr-) using electro-
poration and selected as described (Mack et al., 1995).
Fluorescence-activated cell sorting (FACS) analysis
Human TIMP-1, MMP-2 and MMP-9 were identified on the cell
surface of CHO and U-2 OS by FACS analysis. Cells were
detached with 1.5 mM EDTA (Biochrom) in 1= PBS and incu-
bated for 60 min on ice with the TIMP-1 antibody (Calbiochem/
Merck, Darmstadt, Germany), anti-human MMP-2 antibody (Cal-
biochem/Merck) (5 mg/ml), anti-human MMP-9 antibody (Onco-
gene, Bad Soden, Germany) (5 mg/ml) or IgG1k (Sigma-Aldrich,
Taufkirchen, Germany) (5 mg/ml) isotype control. The cells were
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 11:56
Biological activity of GPI-anchored TIMP-1 protein 661
Figure 5 Effect of rTIMP-1 and TIMP-1-GPI protein on the pro-
liferation of human dermal microvascular endothelial cells and
primary human dermal fibroblasts.
(A) The TIMP-1-GPI protein is more effective in inducing prolif-
eration of the microvascular endothelial cells. (B) In contrast,
both rTIMP-1 and TIMP-1-GPI moderately suppress the prolif-
eration of primary dermal fibroblast cells.
Figure 6 Effect of the GPI-anchored TIMP-1 protein on micro-
vascular endothelial cell migration.
The Figure shows a significant suppression of migration in
response to 4 ng/ml bFGF. In contrast, rTIMP-1 shows a less
pronounced effect on migration.
washed three times with 1= PBS and incubated with a FTIC-
conjugated donkey anti-mouse (Dako A/S, Glostrup, Denmark)
IgG for 45 min on ice. The cells were washed three times with
1= PBS and analyzed on a flow cytometer (FACS Calibur, Bec-
ton, Dickinson, San Jose, USA) using CellQuest analysis
software.
Purification of TIMP-1-GPI protein
The cells were washed three times with cold 1= PBS and
detached with 1.5 mM EDTA. The cells were rotated 1 h at 48C
with hypertonic lysis buffer (5 mM Tris, 2 mM MgCl, 0.1 mM
EDTA, 1 mM PMSF (Roche, Basel, Switzerland), 2 mg/ml apro-
tinin (Roche), 2 mg/ml leupeptin (Sigma), 1 mg/ml pepstatin A
(Roche), pH 7.4. Cell membranes were isolated with extraction
buffer w100 mM NaCl, 1% Triton X-100 Hydrogenated (Triton X-
100 H; Calbiochem/Merck), 10 mM Tris, 5 mM EDTA, 1 mM
PMSF, 2 mg/ml aprotinin, 2 mg/ml leupeptin, 1 mg/ml pepstatin
A, pH 7.4x and were rotated for 1 h at 48C followed by centri-
fugation at 11 000 g for 20 min at 48C. The supernatant was
used for further purification by FPLC.
DEAE resin (DEAE Sepharose Fast Flow, Amersham Biosci-
ences, Uppsala, Sweden) was used for the initial column puri-
fication step. The column was equilibrated with 100 mM NaCl,
50 mM Tris/HCl, 0.1% Triton X-100 H, pH 7.4. The flow-through
fractions containing TIMP-1-GPI were pooled and the buffer
changed using a desalting column (HiTrap Desalting, Amersham
Biosciences) equilibrated with 100 mM NaCl, 0.1% Triton X-100
H and 10 mM sodium phosphate, pH 7.4. Heparin affinity chro-
matography (heparin Sepharose Fast Flow, Amersham Biosci-
ences) was then used. The column was equilibrated with
100 mM NaCl, 10 mM sodium phosphate, 0.1% Triton X-100 H
pH 7.4 and the TIMP-1-GPI protein was eluted from the heparin
column with 450 mM NaCl, 0.1% Triton X-100 H, 10 mM sodium
phosphate, pH 7.4. Eluted fractions were pooled and 20-fold
concentrated using a Centricon concentrator Amicon Ultra with
pore size of 10 000 MWCO (Millipore, Eschborn, Germany). The
eluted concentrate was then purified by gel filtration using a TSK
G3000SWXL (TOSOH Corporation, Tokyo, Japan) column using
1= PBS and 0.025% Triton X-100 H. The final step used a
desalting column equilibrated with 1=PBS to decrease the con-
centration of Triton X-100 H.
For negative controls the TIMP-1-GPI fusion protein was treat-
ed by heat at 908C for 30 min. While recombinant TIMP-1 is a
very stable protein (Dean and Woessner, 1984) this treatment
was sufficient to block the ‘enhanced’ activity associated with
the addition of a GPI anchor.
Protein concentration levels were routinely determined using
the Quick Start Bradford Assay Kit (Bio-Rad Laboratories,
Munich, Germany) according to the manufacturer’s directions.
Western blot analysis
The purified TIMP-1-GPI was detected using a commercial
Western blot analysis kit (Chemiluminescent Immunodetection
System; Invitrogen, Groningen, The Netherlands) and an anti-
human TIMP-1 (Calbiochem/Merck). Control rhTIMP-1 was
obtained from R&D Systems (Minneapolis, USA).
ELISA
A human TIMP-1 ELISA system was used to monitor levels of
TIMP-1 protein in solution. Coating anti-human TIMP-1 mono-
clonal antibody (MAB970), biotinylated anti-human TIMP-1
detection antibody (BAF970) and recombinant human TIMP-1
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protein (970-TM) were all purchased from R&D Systems GmbH
(Wiesbaden, Germany). The agents were used to construct a
human TIMP-1 specific ELISA using the protocol described in
information sheet catalog number MAB970 (R&D Systems).
GPI anchor cleavage
The GPI-anchored TIMP-1 expressing CHO cells were treated
with 30, 60 and 120 ng/ml phosphatidylinositol-specific phos-
pholipase C (Sigma-Aldrich) in serum-free medium for 30 min at
378C. Supernatants were harvested, and released human TIMP-
1 protein was determined by ELISA.
Incorporation of TIMP-1-GPI into cell membranes
Detached CHO cells or osteosarcoma cells (5–10=106 cells/ml)
were incubated with various concentrations between 10 and
1200 ng/ml of purified hTIMP-1-GPI for 1 h at 378C. The cells
were then washed three times with cold PBS and then analyzed
by FACS or zymography as described above, or ELISA was per-
formed on the pooled supernatants.
Proliferation
To assess the proliferation activity of microvascular endothelial
cells and fibroblasts MTT (Sigma-Aldrich) assays were per-
formed (Banas et al., 2002). 3=104 cells in 100 ml medium were
cultured in 96-well microtiter plates for 24 h under standard con-
ditions to yield firmly attached and stably growing cells. After
discarding supernatants, 50 ml of medium containing native
TIMP-1-GPI, heat-treated TIMP-1-GPI, buffer or rhTIMP-1 were
added and the cells were incubated from 24 to 72 h. Then 50 ml
of a 1 mg/ml solution of MTT was added. After 3 h incubation
at 378C formazan crystals were dissolved by addition 100 ml
isopropanol and 0.04 N HCl. Absorbance was measured at
550 nm using Spectra Fluor and a Tecan ELISA reader. For each
experiment at least 6 wells analyzed per experimental condition
and time point.
Endothelial cell migration assay
Human microvascular endothelial cells were cultured in FCS-free
medium 12 h before the start of the experiment. The cells were
detached and labeled with calcein AM (5 mg/ml) (Molecular
Probes, Eugene, USA) for 1 h before migration. The assay medi-
um wFCS-free medium with 1% BSA (Gibco-BRL, Life Technol-
ogies GmbH)x was used to dilute the TIMP inhibitors. Six
hundred ml of assay medium containing 4 ng/ml bFGF
(PromoCell) or without bFGF were placed in the bottom chamber
of a BD FluoroBlok Insert System with pore size 3 mm (Becton
Dickinson, San Jose, USA) and 50 000 calcein-labeled cells with
and without TIMP-1-GPI in a final volume of 100 ml were placed
in the wells and measured by detection of the fluorescence of
cells migrated through the bottom chamber with an Spectra Flu-
or plus Tecan reader at 485 nm excitation and 515 nm emission.
Data represent the mean of ns3 inserts.
Zymography
U-2 OS HTP 96 cells were cultured in 24-well plates (50 000
cells in each well). The medium was changed after 24 h with
serum-free medium containing the TIMP-1-GPI and rhTIMP-1
and incubated for 24 h and 48 h.
Cell supernatants were analyzed by zymography using 10%
SDS-polyacrylamide gels (Invitrogen) containing 0.1% gelatin
loaded with cell supernatant in a 1:2 dilution with SDS sample
buffer (Invitrogen). MMP-9 enzyme (Amersham Biosciences) was
used as positive control. Following electrophoresis at 130 V for
1.5 h the gels were denatured for 30 min and subsequently
developed. The reaction was stopped after 96 h of incubation
at 378C. Gels were then stained with Coomassie Brilliant Blue
and destained with deionized Water.
Assay of TIMP-1 activity
The inhibitory activity of the TIMP-1-GPI protein was measured
using the EnChek Gelatinase Assay Kit (Molecular Probes).
MMP-9 (Amersham Bioscience) and MMP-2 (Sigma-Aldrich)
were used to compare the inhibitory properties of hTIMP-1-GPI
and rhTIMP-1. The Kit consists of highly quenched, fluorescence
labeled gelatin. Upon proteolytic digestion, green fluorescence
is revealed and monitored with a excitation 485 nm and emission
515 nm using a Spectra Fluor plus Tecan ELISA reader. Two
mmol of each enzyme (MMP-2 and MMP-9) were placed in a
96-well microplate. Twenty ml of substrate (1 mg/ml) were added
into each well and increasing concentrations of the inhibitors
(0.5–30 mmol) were added to the wells. The samples were incu-
bated at room temperature protected from light for 120 min and
fluorescence was measured every 30 min. The resulting data
from 30 to 120 min were essentially equivalent. The no-MMP
control was used to detect the zero point of fluorescence for the
conjugated substrate and the no-inhibitor point was used to
determine the fluorescence quench of the substrate with MMP
but without inhibitor.
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